Table 5.

Molecular response among patients achieving complete cytogenetic response

Response	Imatinib resistant		Imatinib intolerant		Total
	No.	%	No.	%	No.	%
Cumulative response*
Patients in subgroup analysis	55		23		78
Major	35	64	15	65	50	64
Complete	27	49	14	61	41	53
Reason for exclusion from analysis
No assessment†	70		21		91
Did not achieve complete cytogenetic response	75		44		119

^*Major molecular response = ≥ 3 log reduction from standardized baseline Bcr-Abl:Abl ratio. Complete molecular response = undetectable Bcr-Abl, with a sensitivity of ≥ 5 log. Molecular response was not assessed according to the International Scale.

^†Because of logistical constraints, 4 countries (China, India, Russia, and South Africa) did not evaluate molecular response.